Table 2.
CFS patients (n = 120) | p valuea | Healthy controls (n = 68) | CFS, Fukuda subgroup (n = 88) | p valuea | CFS, Canada 2003 subgroup (n = 46) | p valuea | |||||
---|---|---|---|---|---|---|---|---|---|---|---|
Plasma TGF-β1 (pg/ml) Median, IQR |
4927 | 5157 | 0.482 | 5692 | 6350 | 4944 | 4276 | 0.599 | 4880 | 6247 | 0.831 |
Plasma TGF-β2 (pg/ml) Mean, SD |
758 | 262 | 0.928 | 754 | 278 | 712 | 246 | 0.809 | 780 | 252 | 0.621 |
Plasma TGF-β3 (pg/ml) Median, IQR |
230 | 227 | 0.901 | 251 | 250 | 230 | 208 | 0.990 | 243 | 254 | 0.760 |
TGF transforming growth factor beta, SD standard deviation, IQR interquartile range
aCompared with healthy controls. Statistical comparisons across groups are based upon Independent sample t test or Mann–Whitney test as appropriate